article thumbnail

New Class of Antibiotic Found That Kills Deadly Drug-Resistant Superbug

AuroBlog - Aurous Healthcare Clinical Trials blog

Researchers have identified an entirely new class of antibiotic that can kill bacteria that are resistant to most current drugs.

Bacterium 242
article thumbnail

Common bacteria modified to make designer sugar-based drug

Scienmag

Process paves a road to safe, ethical, and fast drug manufacturing Credit: Rensselaer Polytechnic Institute TROY, N.Y. — Envisioning an animal-free drug supply, scientists have — for the first time — reprogrammed a common bacterium to make a designer polysaccharide molecule used in pharmaceuticals and nutraceuticals.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Treating TB: uOttawa scientists collaborate to identify new drug for unique therapeutic approach

Scienmag

The disease is caused by a bacterium, Mycobacterium […].

article thumbnail

Lumen Bioscience’s LMN-201 secures FDA fast track status to treat CDI

Pharmaceutical Technology

Biotechnology company Lumen Bioscience has secured fast track designation from the US Food and Drug Administration (FDA) for LMN-201 for the treatment and prevention of C difficile infection (CDI). It is compatible with standard-of-care antibiotics. It is compatible with standard-of-care antibiotics.

Bacterium 130
article thumbnail

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

pharmaphorum

Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria (PKU) next year, after reporting solid proof-of-concept data. The post Synlogic preps phenylketonuria drug for phase 3 after mid-stage win appeared first on.

Drugs 98
article thumbnail

Nestle gets closer to Seres, pledging $525m for microbiome C. diff drug

pharmaphorum

Swiss food giant Nestle has firmed up its five-year-old alliance with US microbiome specialist Seres, paying $175 million upfront for North American co-marketing rights to its lead drug for Clostridium difficile infections. diff drug appeared first on. billion, but only included markets outside North America.

article thumbnail

#news #biotech Common bacteria modified to make designer sugar-based drug

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Common bacteria modified to make designer sugar-based drug.Envisioning an animal-free drug supply, scientists have—for the first time—reprogrammed a common bacterium to make a designer polysaccharide molecule used … Continue (..)